Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hannah Le

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
BiomarkersHannah Le, Roger Raymond, Neil Vasdev, et al.
Lung Cancer (Amsterdam, Netherlands)|October 5, 2024
Systematic review and network meta-analysis of lorlatinib with comparison to other anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) as first-line treatment for ALK-positive advanced non-smallcell lung cancer (NSCLC)Sai-Hong Ou, Hannah Kilvert, Jane Candlish, et al.
International Psychogeriatrics|November 24, 2012
The Birmingham Relationship Continuity Measure: the development and evaluation of a measure of the perceived continuity of spousal relationships in dementiaGerard A Riley, Gemma Fisher, Barbara F Hagger, et al.
Lung Cancer (Amsterdam, Netherlands)|May 15, 2024
Efficacy and safety of crizotinib in the treatment of advanced non-small cell lung cancer with ROS1 gene fusion: a systematic literature review and meta-analysis of real-world evidenceErnest Nadal, Nada Rifi, Sarah Kane, et al.
Cancer Medicine|March 18, 2021
Overall survival, adverse events, and economic burden in patients with chronic lymphocytic leukemia receiving systemic therapy: Real-world evidence from the medicare populationRavi K Goyal, Saurabh P Nagar, Shaum M Kabadi, et al.
Organic Letters|August 22, 2025
From Aqua Green to Deep Red in One Step: Targeted Design of a Highly Luminescent Phosphacyclic Vat Orange 3 DyeReza Dadgaryeganeh, Hannah Le, Sergio Ambrico, et al.
Current Medical Research and Opinion|August 22, 2022
Risk of stroke/systemic embolism, major bleeding, and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran, or rivaroxaban compared with warfarin in the United States medicare population: updated analysisAlpesh Amin, Allison Keshishian, Dionne M Hines, et al.
Lung Cancer Management|February 3, 2026
Cost of managing brain metastases in ALK-positive advanced NSCLC patients receiving first-line ALK TKIs in ChinaBingqi Hu, Jing Xue, Dingsiman Li, et al.
Future Oncology (London, England)|November 16, 2021
Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemiaJing-Zhou Hou, Kellie Ryan, Senxi Du, et al.
Current Medical Research and Opinion|June 22, 2017
Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare populationAlpesh Amin, Allison Keshishian, Jeffrey Trocio, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
BiomarkersHannah Le, Roger Raymond, Neil Vasdev, et al.
Lung Cancer (Amsterdam, Netherlands)|October 5, 2024
Systematic review and network meta-analysis of lorlatinib with comparison to other anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) as first-line treatment for ALK-positive advanced non-smallcell lung cancer (NSCLC)Sai-Hong Ou, Hannah Kilvert, Jane Candlish, et al.
International Psychogeriatrics|November 24, 2012
The Birmingham Relationship Continuity Measure: the development and evaluation of a measure of the perceived continuity of spousal relationships in dementiaGerard A Riley, Gemma Fisher, Barbara F Hagger, et al.
Lung Cancer (Amsterdam, Netherlands)|May 15, 2024
Efficacy and safety of crizotinib in the treatment of advanced non-small cell lung cancer with ROS1 gene fusion: a systematic literature review and meta-analysis of real-world evidenceErnest Nadal, Nada Rifi, Sarah Kane, et al.
Cancer Medicine|March 18, 2021
Overall survival, adverse events, and economic burden in patients with chronic lymphocytic leukemia receiving systemic therapy: Real-world evidence from the medicare populationRavi K Goyal, Saurabh P Nagar, Shaum M Kabadi, et al.
Organic Letters|August 22, 2025
From Aqua Green to Deep Red in One Step: Targeted Design of a Highly Luminescent Phosphacyclic Vat Orange 3 DyeReza Dadgaryeganeh, Hannah Le, Sergio Ambrico, et al.
Current Medical Research and Opinion|August 22, 2022
Risk of stroke/systemic embolism, major bleeding, and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran, or rivaroxaban compared with warfarin in the United States medicare population: updated analysisAlpesh Amin, Allison Keshishian, Dionne M Hines, et al.
Lung Cancer Management|February 3, 2026
Cost of managing brain metastases in ALK-positive advanced NSCLC patients receiving first-line ALK TKIs in ChinaBingqi Hu, Jing Xue, Dingsiman Li, et al.
Future Oncology (London, England)|November 16, 2021
Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemiaJing-Zhou Hou, Kellie Ryan, Senxi Du, et al.
Current Medical Research and Opinion|June 22, 2017
Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare populationAlpesh Amin, Allison Keshishian, Jeffrey Trocio, et al.
Pageof 2